Evaluation of the <i>In Vitro</i> Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates

Abstract

The novel fluorocycline antibiotic eravacycline is in development for use in the treatment of serious infections caused by susceptible and multidrug-resistant (MDR) aerobic and anaerobic Gram-negative and Gram-positive pathogens. Eravacycline and 11 comparator antibiotics were tested against recent anaerobic clinical isolates, including MDR <i>Bacteroides</i> spp. and <i>Clostridium difficile</i> Eravacycline was potent <i>in vitro</i> against all the isolates tested, including strains with tetracycline-specific resistance determinants and MDR anaerobic pathogens resistant to carbapenems and/or β-lactam-β-lactamase inhibitor combinations.